What Is CJC/IPA Blend? Research Evidence & Profile

What Is CJC-1295 No DAC + Ipamorelin?

CJC-1295 No DAC + Ipamorelin is a named blend that should remain distinct from both CJC-1295 with DAC and single-ingredient peptide entries. This page identifies the material as CJC-1295 No DAC + Ipamorelin Blend (CJC/IPA), with amino acid count CJC-1295 (no DAC): 29 Ipamorelin: 5; synonyms Mod-GRF(1-29) / Ipamorelin blend. The CJC-1295 No DAC + Ipamorelin identifiers distinguish this catalogue entry from similarly named compounds, fragments, modified analogues, and multi-component formulations.

This is a multi-component catalogue blend, so a single molecular formula, molecular weight or CAS number is not assigned to the combined product.

Evidence at a Glance

0ClinicalTrials.gov query records

0PubMed query records

0Selected publications shown

Sources: ClinicalTrials.gov query · PubMed query · Retrieved 2026-10-06

Mechanism & Pharmacology

The research record for CJC-1295 No DAC + Ipamorelin is organized around named-blend identification, peptide comparison, signaling-literature review, and analytical blend characterization. For CJC-1295 No DAC + Ipamorelin, those subjects define the literature and analytical context of this specific research peptide; they do not establish a clinical indication, administration route, or expected outcome.

Mechanistic or pathway language defines a research scope. It does not establish that a catalogue product produces a clinical effect.

Clinical Development

Selected exact-query registry records are shown below. Desktop displays up to six; mobile displays up to three.

NCT ID / Study	Phase	Status	Context	Last registry update
No exact-match registry records were returned by the displayed query at the retrieval time.

Source: ClinicalTrials.gov search · Retrieved 2026-10-06

Selected Literature0 important records shown

Selected Literature

No exact-match PubMed records were selected by the displayed query at the retrieval time.

Source: PubMed search results · Retrieved 2026-10-06

Identity & ChemistryProduct-form fields

Identity & Chemistry

Compound / Blend: CJC-1295 No DAC + Ipamorelin Blend (CJC/IPA)
Available Specifications: 10mg
Pack Format: 10 Vials
CAS Number: CJC-1295 (no DAC): 863288-34-0 Ipamorelin: 170851-70-4
Molecular Formula: CJC-1295 (no DAC): C152H252N44O42 Ipamorelin: C38H49N9O5
Molecular Weight: CJC-1295 (no DAC): 3367.93 Ipamorelin: 711.85
Amino Acid Count: CJC-1295 (no DAC): 29 Ipamorelin: 5
Sequence: CJC-1295 (no DAC / Mod GRF 1-29): Tyr-D-Ala-Asp-Ala-Ile-Phe-Thr-Gln-Ser-Tyr-Arg-Lys-Val-Leu-Ala-Gln-Leu-Ser-Ala-Arg-Lys-Leu-Leu-Gln-Asp-Ile-Met-Ser-Arg-NH2 Ipamorelin: Aib-His-D-2-Nal-D-Phe-Lys-NH2
Synonyms: Mod-GRF(1-29) / Ipamorelin blend
Physical Form: Lyophilized powder

This is a multi-component catalogue blend, so a single molecular formula, molecular weight or CAS number is not assigned to the combined product.

Source: NOVABIO product identity record · No single PubChem record is asserted for this catalogue entry.

Research Tools for CJC-1295 No DAC + Ipamorelin

Review the selected registry records and open the module-level ClinicalTrials.gov query for the current result set.

Open Clinical Development

Use the complete NOVABIO documentation library to review currently available batch records.

Open Lab Results & COA

Storage & Laboratory HandlingDocumentation-led controls

Storage & Laboratory Handling

Confirm the exact material form, lot, supplied state and storage statement from the product label and corresponding batch documentation. Do not infer handling conditions from a different compound, strength or external clinical publication.

Regulatory Status

FDA status must be checked by exact drug product, formulation and indication; catalogue availability does not establish approval.

Source: FDA Drugs@FDA · Checked 2026-10-06

Authoritative Data Summary

CJC-1295 No DAC + Ipamorelin Research Summary

Identity

CJC-1295 No DAC + Ipamorelin Blend (CJC/IPA); specifications: 10mg. This is a multi-component catalogue blend, so a single molecular formula, molecular weight or CAS number is not assigned to the combined product.

Mechanism

Evidence

0 registry records and 0 PubMed records were returned by the displayed query on 2026-10-06; counts are not quality ratings.

Regulatory context

FDA status must be checked by exact drug product, formulation and indication; catalogue availability does not establish approval.

CJC-1295 No DAC + Ipamorelin is represented here by the catalogue identity CJC-1295 No DAC + Ipamorelin Blend (CJC/IPA). This is a multi-component catalogue blend, so a single molecular formula, molecular weight or CAS number is not assigned to the combined product. The product record lists 10mg as the currently available specifications. The research context is organized around this product-specific scope: The research record for CJC-1295 No DAC + Ipamorelin is organized around named-blend identification, peptide comparison, signaling-literature review, and analytical blend characterization. For CJC-1295 No DAC + Ipamorelin, those subjects define the literature and analytical context of this specific research peptide; they do not establish a clinical indication, administration route, or expected outcome. The synchronized searches returned 0 ClinicalTrials.gov records and 0 PubMed records for the displayed query. A registry count includes records with different designs, statuses and populations, while a publication count can include reviews, preclinical work and unrelated uses of a shared abbreviation; neither count is a quality score. For regulatory interpretation, FDA status must be checked by exact drug product, formulation and indication; catalogue availability does not establish approval. Clinical findings apply only to the studied drug product, formulation, population and protocol. NOVABIO product specifications and batch documentation are separate catalogue records and do not inherit clinical outcomes from external studies. This profile supports identity checking, source tracing and laboratory record review; it does not certify a batch, recommend treatment, provide dosing instructions or replace current official labeling and professional judgment.

Sources: PubMed · ClinicalTrials.gov · FDA · NOVABIO product record

FAQ4 evidence-bounded answers

CJC-1295 No DAC + Ipamorelin FAQ

What is CJC-1295 No DAC + Ipamorelin?

What research records are indexed for CJC-1295 No DAC + Ipamorelin?

The synchronized query returned 0 ClinicalTrials.gov records and 0 PubMed records on 2026-10-06; review the linked searches because counts and record status can change.

Is CJC-1295 No DAC + Ipamorelin FDA approved?

FDA status must be checked by exact drug product, formulation and indication; catalogue availability does not establish approval.

Does this page provide dosing guidance?

No. This research profile provides identity, evidence, chemistry, regulatory and documentation context without dosing or treatment instructions.

Sources, Methodology & Last Verified

Official sources: ClinicalTrials.gov, NCBI PubMed, FDA, available PubChem records, and NOVABIO product and COA records.
Query retrieved: 2026-10-06T12:08:49Z
Inclusion: Exact identity terms and traceable registry, publication, chemistry, regulatory or catalogue fields.
Limitations: Search counts can include mixed evidence types and shared-name records; individual records require direct review.
Prepared by: NOVABIO Research
Reviewed date: 2026-10-06
Editorial methodology: How NOVABIO builds Research Profiles
Corrections contact: Contact NOVABIO with the page URL and source record.